Ran Frenkel

2021

In 2021, Ran Frenkel earned a total compensation of $1.6M as Executive Vice President, Chief Development Officer at Karyopharm Therapeutics.

Compensation breakdown

Bonus$50,000
Non-Equity Incentive Plan$172,000
Option Awards$588,826
Salary$429,525
Stock Awards$320,509
Other$16,343
Total$1,577,203

Frenkel received $588.8K in option awards, accounting for 37% of the total pay in 2021.

Frenkel also received $50K in bonus, $172K in non-equity incentive plan, $429.5K in salary, $320.5K in stock awards and $16.3K in other compensation.

Rankings

In 2021, Ran Frenkel's compensation ranked 7,049th out of 12,415 executives tracked by ExecPay. In other words, Frenkel earned more than 43.2% of executives.

ClassificationRankingPercentile
All
7,049
out of 12,415
43rd
Division
Manufacturing
3,084
out of 5,501
44th
Major group
Chemicals And Allied Products
1,363
out of 2,371
43rd
Industry group
Drugs
1,213
out of 2,092
42nd
Industry
Pharmaceutical Preparations
885
out of 1,542
43rd
Source: SEC filing on April 8, 2022.

Frenkel's colleagues

We found five more compensation records of executives who worked with Ran Frenkel at Karyopharm Therapeutics in 2021.

2021

Richard Paulson

Karyopharm Therapeutics

Chief Executive Officer

2021

Sharon Shacham

Karyopharm Therapeutics

Chief Scientific Officer

2021

Michael Kauffman

Karyopharm Therapeutics

Chief Executive Officer

2021

Michael Mason

Karyopharm Therapeutics

Chief Financial Officer

2021

Jatin Shah

Karyopharm Therapeutics

Chief Medical Officer

News

You may also like